Helus Pharma (TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that CEO Michael Halstead will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit. The virtual event is scheduled for September 23, 2026, at 9 a.m. EDT and will be webcast live. The announcement, disseminated on behalf of Helus Pharma, underscores the company’s growing visibility in the neuropsychiatry space as it advances its pipeline of proprietary treatments for mental health conditions.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, the company seeks to improve the treatment landscape through durable improvements in mental health.
The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a status that expedites the development and review of drugs for serious conditions. Additionally, Helus Pharma is developing HLP004, also a proprietary NSA, in Phase 2 for generalized anxiety disorder. The company operates in Canada, the United States, the United Kingdom, and Ireland.
Halstead’s participation in the TD Cowen summit is significant because it provides a platform to discuss the potential of NSAs with key stakeholders in the neuropsychiatry field. The event, focused on novel mechanisms, aligns with Helus Pharma’s mission to pioneer new treatments. For investors, the fireside chat may offer insights into the company’s clinical progress and strategic direction. The full press release can be viewed at https://nnw.fm/8dLEZ. For more information about Helus Pharma, visit www.helus.com.
The announcement was distributed by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and enhanced press release enhancement. The platform also offers social media distribution and a full array of tailored corporate communications solutions.
The upcoming fireside chat matters because it highlights Helus Pharma’s commitment to advancing mental health treatments and provides a window into the company’s clinical milestones. As the demand for effective depression and anxiety therapies grows, Helus Pharma’s NSAs could represent a significant breakthrough if approved. Investors and industry observers will be watching the summit for updates on HLP003 and HLP004, which target conditions affecting millions worldwide. The event also reinforces the role of platforms like NetworkNewsWire in connecting companies with the investment community. For full terms of use and disclaimers, visit https://www.NetworkNewsWire.com/Disclaimer.
